ARCHIVES

FDA Approves Evista for Breast Cancer Risk Reduction.

This article is from The Cancer Letter archive.

Vol. 33 No. 33 | September 14, 2007

Download PDF Visit The Full Archive

Related Articles

Phase II Study Finds Dasatinib May Overcome ALL Resistance

May 25, 2007

In Brief: NCAB To Hear NCI Staff Plans For Implementing Recommendation On Nutrition & Cancer Task Force

October 1, 1982

In Brief: NCAB to Hear Report On Treatment Programs, Discuss Hogness Plan For New Type of Review

November 3, 1978

FDA Proposes New User Fees for Generics and Biosimilar Products

January 20, 2012

Small Study: Radiation, Chemo May Better Control Anal Cancer

November 26, 2010

Group Chairmen Criticize NCI Budget Priorities

July 11, 2003